What do transgender patients teach us about Idiopathic Intracranial Hypertension?

Hornby, Catherine; Mollan, Susan; Mitchell, James; Markey, Keira Annie; Yangou, Andreas; Wright, Ben; O'Reilly, Michael; Sinclair, Alexandra

DOI: 10.1080/01658107.2017.1316744

License: Creative Commons: Attribution (CC BY)

Citation for published version (Harvard):

Link to publication on Research at Birmingham portal

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• Users may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.
What Do Transgender Patients Teach Us About Idiopathic Intracranial Hypertension?

Catherine Hornby, Susan P. Mollan, James Mitchell, Keira Annie Markey, Andreas Yangou, Ben L. C. Wright, Michael W. O'Reilly & Alexandra J. Sinclair

To cite this article: Catherine Hornby, Susan P. Mollan, James Mitchell, Keira Annie Markey, Andreas Yangou, Ben L. C. Wright, Michael W. O'Reilly & Alexandra J. Sinclair (2017): What Do Transgender Patients Teach Us About Idiopathic Intracranial Hypertension?, Neuro-Ophthalmology, DOI: 10.1080/01658107.2017.1316744

To link to this article: http://dx.doi.org/10.1080/01658107.2017.1316744
Idiopathic intracranial hypertension (IIH) is a disorder of raised intracranial pressure (ICP), typically presenting with headaches, papilloedema, and visual loss. Headaches can be severe, causing significant morbidity, although there is increasing recognition of the variability in their presentation. There is also a recognised subset of patients where papilloedema is not present, IIH without papilloedema (IIHWOP). The condition has a predilection for obese women of childbearing age, yet the reasons for this are not clear.

A condition with similar phenotypic characteristics of obese, young women is polycystic ovary syndrome (PCOS). Androgen excess is a defining feature of PCOS. There is an increased prevalence of PCOS in the IIH population, with reports of up to 57% of IIH patients also having PCOS, compared with a prevalence of 5–10% in the general population. It is interesting to speculate that IIH, akin to PCOS, could be driven by androgen excess. In support of this, a study has found that hyperandrogenism is linked with younger age of onset of IIH but is not associated with body mass index (BMI), waist-to-hip ratios, or duration of IIH.

Karyotypically female patients undergoing female-to-male (FTM) gender reassignment with testosterone therapy offer an important opportunity to increase our understanding of the role of androgens in IIH. Here, we present the case of a patient undergoing gender reassignment who developed IIH on commencing testosterone therapy.

Case report

A 22-year-old karyotypically 46XX patient undergoing FTM gender reassignment presented with a 6-month history of new daily headaches and 5 months of intermittent visual blurring, pulsatile tinnitus, and nausea. He had started testosterone injections (250 mg 3-monthly) just prior to symptom onset (Figure 1). His visual symptoms progressed, and he began to develop transient visual...
obscurations up to 50 times per day. He presented to his opticians, who noted bilateral papilloedema and referred him to neuro-ophthalmology. Best-corrected visual acuity was 6/9 bilaterally, Ishihara colour vision was normal, and there was no relative afferent pupillary defect (RAPD). He was confirmed to have severe bilateral papilloedema, modified Frisén grade 3 in the right eye and grade 4 in the left eye, with no sixth nerve palsy. Spectral-domain optical coherence tomography was performed (Figure 2), and the overall maximum retinal nerve fibre layer (RNFL) height was 1226 μm for the left eye and 1218 μm for the right eye. Goldmann visual fields showed bilateral increase in the blind spot, loss of some static central points in the right eye, with the left eye showing an increased nasal step. Magnetic resonance (MR) imaging of the brain (Siemens 3.0 Tesla) showed a partial empty sella on T2-weighted imaging, and MR venography demonstrated no cerebral sinus thrombosis. Two lumbar punctures a few days apart recorded opening pressures of 40 and 39 cm cerebrospinal fluid (CSF). Although he was classed as overweight on starting testosterone injections (BMI 27.9 kg/m²), his weight had only increased over the period of the testosterone therapy to a very small degree (+3.3 kg in 6 months). His full blood count, renal and liver functions, and inflammatory markers were normal. His regular medications consisted of regular pain relief with codeine and naproxen, zopiclone 7.5 mg, sertraline 50 mg OD, desogestrel 75 μg (for suppression of menses and endometrial protection), and 3-monthly testosterone injections (250 mg). There was no evidence of other secondary cause of raised ICP. Due to emergent deterioration in visual function, he was referred for CSF diversion with a lumbo-peritoneal shunt.

Following lumbo-peritoneal shunt insertion, papilloedema settled. The patient decided to continue testosterone injections; the testosterone was initiated at 6 months.

Figure 1. Profile of serum testosterone over time since initiation of therapy, with first presentation at 6 months.

Figure 2. Composite figure showing colour fundus photographs of the papilloedema affecting the optic nerve head (ONH) of the right (A) and left (C) eyes. Optical coherence tomography (OCT) SPECTRALIS HRA+OCT (Heidelberg Engineering, Heidelberg, Germany), infrared (IR) images of the ONH, and volume cross-sectional images and the elevated height through the centre of the ONH of the right (E) and left (F) eyes. OCT IR disc volume reconstructions for right (B) and left (D) eyes.
levels remained elevated (Figure 1) and his weight remains stable. At 18 months post shunt insertion, the IIH remained in remission and he went on to have a bilateral mastectomy.

**Discussion**

This case is unusual, as it reports the development of IIH in a transgender patient on testosterone therapy. The temporal relationship of initiation of testosterone therapy and the onset of symptoms in this case may suggest a link between raised intracranial pressure and testosterone. However, this occurrence is not in isolation, as four other reports in the literature document similar cases of IIH arising in patients undergoing gender reassignment with testosterone therapy, with three having a temporal relationship with commencing testosterone therapy.\(^{10,11,13}\) All cases reported were reassigning their gender from female to male (Table 1).

Transgender patients who develop IIH provide an insight into the potentially pathogenic role of testosterone in IIH. The predilection of the disease for a particular gender would suggest that hormones may play a role in pathogenesis; however, previous studies into the role of oestrogens were inconclusive and have not been replicated.\(^{14,15}\) It may be that the class of hormones that need further investigation are the androgens, as highlighted by this case report and the previous cases (Table 1), coupled with the observation that another androgen dysregulated condition, PCOS, shares a strikingly similar clinical phenotype. Furthermore, one study reports an increased incidence (58%) of PCOS in FTM patients prior to hormonal therapy.\(^{16}\) It is notable that IIH has also been reported in men with hypogonadism, with cases described in men after androgen deprivation therapy for prostate cancer.\(^{17}\) Additionally, men with IIH are more likely to have symptoms associated with testosterone deficiency.\(^{18}\) This raises the prospect of a “pathophysiological window” of circulating testosterone levels in humans, with levels above the normal reference range for females, but below the normal reference range for men, associated with metabolic perturbations, including increased visceral fat deposition, insulin resistance, and fatty liver disease.\(^{19}\) Serum testosterone levels in the cases described above were within this window when first presentation occurred. It is therefore feasible that IIH is a distinct neuro-metabolic complication of circulating testosterone levels within this range. These observations present an interesting avenue for new research in IIH and warrant the need for further detailed characterisation of the androgen metabolic phenotype in this condition.

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Gender reassignment</th>
<th>Symptom occurrence</th>
<th>Testosterone temporally causative</th>
<th>Body mass index (kg/m(^2))</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case presented</td>
<td>2017</td>
<td>FTM</td>
<td>Symptoms correlate with testosterone commencing</td>
<td>Yes</td>
<td>27.9</td>
<td>LP shunt</td>
<td>Remission of raised intracranial pressure</td>
</tr>
<tr>
<td>Buchanan et al.</td>
<td>2017</td>
<td>FTM</td>
<td>Increasing dose of testosterone, and increased weight</td>
<td>Yes</td>
<td>Not known</td>
<td>Treatment was initially reducing testosterone hormone therapy by 50% and acetazolamide. Then subsequent weight loss Swapped to longer-acting testosterone therapy and started acetazolamide</td>
<td>Remission</td>
</tr>
<tr>
<td>Park et al.</td>
<td>2014</td>
<td>FTM</td>
<td>Patient was on testosterone</td>
<td>Yes</td>
<td>Not known</td>
<td>Swapped to longer-acting testosterone therapy and started acetazolamide</td>
<td>Remission</td>
</tr>
<tr>
<td>Mowl et al.</td>
<td>2009</td>
<td>FTM</td>
<td>Patient was on testosterone</td>
<td>Yes</td>
<td>27</td>
<td>Reducing testosterone therapy and Diamox Initially acetazolamide, due to side effects switched to frusemide and topiramate. Subsequent unilateral optic nerve sheath fenestration</td>
<td>Remission</td>
</tr>
<tr>
<td>Sheets et al.</td>
<td>2007</td>
<td>FTM</td>
<td>Symptoms started 10 months after discontinuing testosterone</td>
<td>No</td>
<td>29.8</td>
<td>Reducing testosterone therapy and Diamox Initially acetazolamide, due to side effects switched to frusemide and topiramate. Subsequent unilateral optic nerve sheath fenestration</td>
<td>Remission</td>
</tr>
</tbody>
</table>
**Declaration of interest**

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.

**Funding**

C.H. is funded by an intercalating student award from the Association of British Neurologists. A.S. is funded by an NIHR Clinician Scientist Fellowship (NIHR-CS-011-028) and by the Medical Research Council, UK (MR/K015184/1).

**ORCID**

Catherine Hornby  [http://orcid.org/0000-0003-2218-9695](http://orcid.org/0000-0003-2218-9695)

**References**


